Intellia Therapeutics (NASDAQ:NTLA – Get Rating) had its target price upped by JMP Securities from $106.00 to $111.00 in a research note published on Monday, The Fly reports. They currently have a market outperform rating on the stock.
Other research analysts have also issued research reports about the stock. StockNews.com upgraded shares of Intellia Therapeutics to a sell rating in a research note on Friday, August 5th. The Goldman Sachs Group cut their price objective on shares of Intellia Therapeutics from $206.00 to $180.00 and set a buy rating on the stock in a research note on Tuesday, May 24th. Credit Suisse Group increased their price objective on shares of Intellia Therapeutics to $101.00 in a research note on Tuesday, August 9th. Chardan Capital reiterated a buy rating and issued a $146.00 price objective on shares of Intellia Therapeutics in a research note on Friday. Finally, Citigroup assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, September 1st. They issued a sell rating and a $50.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $123.82.
Intellia Therapeutics Trading Down 3.4 %
Shares of Intellia Therapeutics stock opened at $63.47 on Monday. Intellia Therapeutics has a 12-month low of $37.08 and a 12-month high of $155.63. The firm has a market capitalization of $4.82 billion, a price-to-earnings ratio of -11.86 and a beta of 2.02. The firm’s 50 day simple moving average is $62.95 and its two-hundred day simple moving average is $57.99.
Hedge Funds Weigh In On Intellia Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Intellia Therapeutics during the first quarter valued at $766,000. Frazier Life Sciences Management L.P. purchased a new position in Intellia Therapeutics during the first quarter valued at $14,802,000. Precision Wealth Strategies LLC lifted its holdings in Intellia Therapeutics by 28.4% during the first quarter. Precision Wealth Strategies LLC now owns 12,174 shares of the company’s stock valued at $885,000 after purchasing an additional 2,694 shares in the last quarter. Elmwood Wealth Management Inc. lifted its holdings in Intellia Therapeutics by 0.4% during the second quarter. Elmwood Wealth Management Inc. now owns 67,899 shares of the company’s stock valued at $3,514,000 after purchasing an additional 300 shares in the last quarter. Finally, Prospera Financial Services Inc purchased a new position in Intellia Therapeutics during the first quarter valued at $32,000. 88.18% of the stock is owned by hedge funds and other institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
- Get a free copy of the StockNews.com research report on Intellia Therapeutics (NTLA)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.